Suppr超能文献

[地高辛、洋地黄毒苷及其心脏活性代谢产物在人心脏和肾脏组织中的分布。一项尸检研究]

[Distribution of digoxin, digitoxin and their cardioactive metabolites in human heart and kidney tissue. A postmortem study].

作者信息

Plum J, Daldrup T

出版信息

Z Rechtsmed. 1985;94(4):257-72. doi: 10.1007/BF00205094.

Abstract

A method was developed for the specific determination of digoxin and digitoxin, as well as their semisynthetic derivatives and dependent cardioactive metabolites, in autopsy samples of heart and kidney. A collective of six patients on long-term treatment with therapeutic doses of beta-acetyldigoxin had a mean myocardial digoxin content of 46.1 +/- 25.0 ng/g (SD); kidney: 50.3 +/- 30.3 ng/g. Digoxigenin bisdigitoxoside represented the second most important metabolite in heart and kidney; digoxigenin monodigitoxoside and digoxigenin follow, respectively. In a collective of seven patients on maintenance treatment with digitoxin, the mean tissue levels were higher but the metabolic pattern was similar (myocardial digitoxin content: 78.9 +/- 38.4 ng/g, renal content: 104.1 +/- 44.1 ng/g). The amount of digoxin formed by hydroxylation under long-term treatment with digitoxin in heart and kidney were approximately 10 ng/g. A case of digoxin intoxication differed both in the tissue content and in the metabolic distribution.

摘要

已开发出一种用于在心脏和肾脏尸检样本中特异性测定地高辛、洋地黄毒苷及其半合成衍生物和相关心脏活性代谢物的方法。一组6名长期接受治疗剂量β-乙酰地高辛治疗的患者,心肌地高辛平均含量为46.1±25.0 ng/g(标准差);肾脏:50.3±30.3 ng/g。洋地黄毒苷双洋地黄毒糖甙是心脏和肾脏中第二重要的代谢物;其次分别是洋地黄毒苷单洋地黄毒糖甙和洋地黄毒苷元。在一组7名接受洋地黄毒苷维持治疗的患者中,平均组织水平较高,但代谢模式相似(心肌洋地黄毒苷含量:78.9±38.4 ng/g,肾脏含量:104.1±44.1 ng/g)。在心脏和肾脏中,长期用洋地黄毒苷治疗时通过羟基化形成的地高辛量约为10 ng/g。1例地高辛中毒病例在组织含量和代谢分布方面均有所不同。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验